New hope for hepatitis b: experimental drug shows promise in mid-stage trial
NCT ID NCT04412863
First seen Apr 19, 2026 · Last updated Jun 18, 2026 · Updated 16 times
Summary
This study tested an experimental drug called VIR-2218 in 84 adults with chronic hepatitis B. Some participants received VIR-2218 alone, and others got it combined with pegylated interferon. The main goals were to check safety and how well the drug works against the virus. The study is complete, and results will help decide if further testing is needed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Investigative Site
Birtinya, Queensland, 4575, Australia
-
Investigative Site
Fitzroy, Victoria, 3168, Australia
-
Investigative Site
Batu Caves, 68100, Malaysia
-
Investigative Site
Kajang, 43000, Malaysia
-
Investigative Site
Kuala Lumpur, 59100, Malaysia
-
Investigative Site
Kuantan, 25100, Malaysia
-
Investigative Site
Auckland, 1010, New Zealand
-
Investigative Site
Auckland, 2025, New Zealand
-
Investigative Site
Busan, 49241, South Korea
-
Investigative Site
Chuncheon, 24253, South Korea
-
Investigative Site
Daegu, 41944, South Korea
-
Investigative Site
Seoul, 03080, South Korea
-
Investigative Site
Seoul, 05505, South Korea
-
Investigative Site
Yangsan, 50612, South Korea
-
Investigative Site
Bangkok, 10330, Thailand
-
Investigative Site
Bangkok, 10400, Thailand
-
Investigative Site
Bangkok, 10700, Thailand
-
Investigative Site
Chiang Mai, 50200, Thailand
-
Investigative Site
Hat Yai, 90110, Thailand
-
Investigative Site
Khlong Luang, 12120, Thailand
-
Investigative Site
Khon Kaen, 40002, Thailand
-
Investigative site
Hong Kong, Hong Kong
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.